A randomized, double-blind, phase (Ph) III study of the irinotecan-based chemotherapy FOLFIRI plus ramucirumab (RAM) or placebo (PL) in patients (pts) with metastatic colorectal carcinoma (mCRC) progressive during or following first-line therapy with bevacizumab (BEV), oxaliplatin (OXALI), and a fluoropyrimidine (FP) (RAISE) (NCT01183780).

Axel Grothey,Josep Tabernero,Philippe Rougier,Shaila Ballal,Heidi M. Crane,Mark D. Rutstein

A randomized, double-blind, phase (Ph) III study of the irinotecan-based chemotherapy FOLFIRI plus ramucirumab (RAM) or placebo (PL) in patients (pts) with metastatic colorectal carcinoma (mCRC) progressive during or following first-line therapy with bevacizumab (BEV), oxaliplatin (OXALI), and a fluoropyrimidine (FP) (RAISE) (NCT01183780).

2017

Axel Grothey
Josep Tabernero
Philippe Rougier
Shaila Ballal
Heidi M. Crane
Mark D. Rutstein

TPS3634 Background: Vascular endothelial growth factor (VEGF) and the VEGF receptor-2 (VEGFR-2) regulate angiogenesis and are overexpressed in CRC. RAM is a fully human IgG1 monoclonal antibody tha...

Keywords:

Angiogenesis
Pathology
Ramucirumab
Irinotecan
Bevacizumab
Oxaliplatin
Vascular endothelial growth factor
Colorectal cancer
Oncology
FOLFIRI
Internal medicine
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations